Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Journal of Cancer Research and Clinical Oncology
Published in: Journal of Cancer Research and Clinical Oncology 3/2012

01-03-2012 | Original Paper

Down-regulation of PDCD4 expression is an independent predictor of poor prognosis in human renal cell carcinoma patients

Authors: Xiancheng Li, Shiyong Xin, Deyong Yang, Xiunan Li, Zhongzhou He, Xiangyu Che, Jianbo Wang, Feng Chen, Xuejian Wang, Xishuang Song

Published in: Journal of Cancer Research and Clinical Oncology | Issue 3/2012

Login to get access

Abstract

Objectives

The tumor suppressor gene entitled programmed cell death 4 (PDCD4) encodes a protein that inhibits neoplastic transformation and invasion. The aim of this study was to investigate the expression of PDCD4 and its prognostic roles in human renal cell carcinoma (RCC).

Materials and methods

A total of 32 paired fresh tumor specimens and adjacent non-cancerous renal tissue from RCC patients by western blot to detect the difference of PDCD4 expression in tumor tissues and non-cancerous tissues. 66 RCC paraffin-embedded specimens and 18 normal renal tissues were analyzed by immunohistochemistry to investigate the association of PDCD4 expression with RCC clinicopathological features.

Results

PDCD4 expression was significantly decreased in RCC compared with normal renal tissues (P = 0.03), and it was found to be significantly associated with RCC metastasis (P = 0.007), tumor T-stage (P = 0.022) and tumor grade (P = 0.015). The mean overall survival was significantly decreased in the low PDCD4 group compared to the high PDCD4 group (low PDCD4: mean overall survival 41.9 months, high PDCD4: mean overall survival 52.9 months, P = 0.008).

Conclusion

PDCD4 expression strongly correlated to RCC stage, tumor grade, tumor metastasis and tumor-related death. PDCD4 expression was also appears to be a marker in RCC prognosis.
Literature
Allgayer H (2010) Pdcd4, a colon cancer prognostic that is regulated by a microRNA. Crit Rev Oncol Hematol 73:185–191PubMedCrossRef
Böhm M, Sawicka K, Siebrasse JP, Brehmer-Fastnacht A, Peters R, Klempnauer KH (2003) The transformation suppressor protein Pdcd4 shuttles between nucleus and cytoplasm and binds RNA. Oncogene 22:4905–4910PubMedCrossRef
Campbell SC, Novick AC, Bukowski RM (2007) Renal tumors. In: Wein AJ, Kavoussi LR, Novick AC, Partin AW, Peters CA (eds) Campbell-Walsh urology, 9th edn. Saunders, Philadelphia, pp 1567–1637
Chen Y, Knosel T, Kristiansen G et al (2003) Loss of PDCD4 expression in human lung cancer correlates with tumour progression and prognosis. J Pathol 200:640–646PubMedCrossRef
Cmarik JL, Min H, Hegamyer G et al (1999) Differentially expressed protein Pdcd4 inhibits tumor promoter-induced neoplastic transformation. Proc Natl Acad Sci USA 96:14037–14042PubMedCrossRef
Dorrello NV, Peschiaroli A, Guardavaccaro D, Colburn NH, Sherman NE, Pagano M (2006) S6K1- and beta TRCP-mediated degradation of PDCD4 promotes protein translation and cell growth. Science 314:467–471PubMedCrossRef
Gao F, Zhang P, Zhou C et al (2007) Frequent loss of PDCD4 expression in human glioma: possible role in the tumorigenesis of glioma. Oncol Rep 17:123–128PubMed
Gao F, Wang X, Zhu F et al (2009) PDCD4 gene silencing in gliomasis associated with 5′CpG island methylation and unfavorable prognosis. J Cell Mol Med 13:4257–4267PubMedCrossRef
Göke R, Barth P, Schmidt A, Samans B, Lankat-Buttgereit B (2004) Programmed cell death protein 4 suppresses CDK1/cdc2 via induction of p21(Waf1/Cip1). Am J Physiol Cell Physiol 287:C1541–C1546PubMedCrossRef
Jansen AP, Camalier CE, Colburn NH (2005) Epidermal expression of the translation inhibitor programmed cell death 4 suppresses tumorigenesis. Cancer Res 65:6034–6041PubMedCrossRef
Lankat-Buttgereit B, Göke R (2009) The tumour suppressor Pdcd4: recent advances in the elucidation of function and regulation. Biol Cell 101:309–317PubMedCrossRef
Lankat-Buttgereit B, Gregel C, Knolle A, Hasilik A, Arnold R, G¨oke R (2004) Pdcd4 inhibits growth of tumor cells by suppression of carbonic anhydrase typeII. Mol Cell Endocrinol 214:149–153PubMedCrossRef
Lankat-Buttgereit B, Lenschen B, Schmidt H, Goke R (2008) The action of Pdcd4 may be cell type specific: evidence that reduction of dUTPase levels might contribute to its tumor suppressor activity in Bon-1 cells. Apoptosis 13:157–164PubMedCrossRef
Leupold JH, Yang HS, Colburn NH, Asangani I, Post S, Allgayer H (2007) Tumor suppressor Pdcd4 inhibits invasion/intravasation and regulates urokinase receptor (u-PAR) gene expression via Sp-transcription factors. Oncogene 26:4550–4562PubMedCrossRef
Ma G, Guo KJ, Zhang H et al (2005) Expression of programmed cell death 4 and its clinicopathological significance in human pancreatic cancer. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 27:597–600PubMed
Matsuhashi S, Narisawa Y, Ozaki I, Mizuta T (2007) Expression patterns of programmed cell death 4 protein in norma human skin and some representative skin lesions. Exp Dermatol 16:179–184PubMedCrossRef
Mudduluru G, Medved F, Grobholz R et al (2007) Loss of programmed cell death 4 expression marks adenoma-carcinoma transition, correlates inversely with phosphorylated protein kinase B, and is an indeoendent prognostic factor in resected colorectal cancer. Cancer 110:1679–1707CrossRef
Murphy WM, Grignon DJ, Perlman EJ (2004) Kidney tumors in adults. In: Murphy WM, Grignon DJ, Perlman EJ (eds) Tumor of the kidney, bladder, and related urinary structures. American registry of pathology, Washington, pp 101–240
Onishi Y, Hashimoto S, Kizaki H (1998) Cloning of the TIS gene suppressed by topoisomerase inhibitors. Gene 215:453–459PubMedCrossRef
Ozpolat B, Akar U, Steiner M et al (2007) Programmed cell death-4 tumor suppressor protein contributes to retinoic acid-induced terminal granulocytic differentiation of human myeloid leukemia cells. Mol Cancer Res 5:95–108PubMedCrossRef
Palamarchuk A, Efanov A, Maximov V, Aqeilan RI, Croce CM, Pekarsky Y (2005) Akt phosphorylates and regulates pdcd4 tumor suppressor protein. Cancer Res 65:11282–11286PubMedCrossRef
Schlichter U, Burk O, Worpenberg S, Klempnauer KH (2001) The chicken Pdcd4 gene is regulated by v-Myb. Oncogene 20:231–239PubMedCrossRef
Shibahara K, Asano M, Ishida Y, Aoki T, Koike T, Honjo T (1995) Isolation of a novel mouse gene MA-3 that is induced upon programmed cell death. Gene 166:297–301PubMedCrossRef
Van Spronsen DJ, Mulders PF, De Mulder PH (2005) Novel treatments for metastatic renal cell carcinoma. Crit Rev Oncol Hematol 55:177–191PubMedCrossRef
Wang X, Wei Z, Gao F et al (2008) Expression and prognostic significance of PDCD4 in human epithelial ovarian carcinoma. Anticancer Res 28:2991–2996PubMed
Wen YH, Shi X, Chiriboga L, Matsahashi S, Yee H, Afonja O (2007) Alterations in the expression of PDCD4 in ductal carcinoma of the breast. Oncol Rep 18:1387–1393PubMed
Yoshinaga H, Matsuhashi S, Fujiyama C, Masaki Z (1999) Novel human PDCD4 (H731) gene expression in proliferative cells is expressed in the small duct epithelial cells of the breast as revealed by an anti-H731 antibody. Pathol Int 49:1067–1077PubMedCrossRef
Zhang Z, DuBois RN (2001) Detection of differentially expressed genes in human colon carcinoma cells treated with a selective COX-2 inhibitor. Oncogene 20:4450–4456PubMedCrossRef
Zhang H, Ozaki I, Mizuta T et al (2006) Involvement of programmed cell death 4 in transforming growth factor-β1-induced apoptosis in human hepatocellular carcinoma. Oncogene 25:6101–6112PubMedCrossRef
Metadata
Title
Down-regulation of PDCD4 expression is an independent predictor of poor prognosis in human renal cell carcinoma patients
Authors
Xiancheng Li
Shiyong Xin
Deyong Yang
Xiunan Li
Zhongzhou He
Xiangyu Che
Jianbo Wang
Feng Chen
Xuejian Wang
Xishuang Song
Publication date
01-03-2012
Publisher
Springer-Verlag
Published in
Journal of Cancer Research and Clinical Oncology / Issue 3/2012
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI
https://doi.org/10.1007/s00432-011-1121-y

Other articles of this Issue 3/2012

Journal of Cancer Research and Clinical Oncology 3/2012 Go to the issue

Original Paper

Reliability of tumor primary cultures as a model for drug response prediction: expression profiles comparison of tissues versus primary cultures from colorectal cancer patients

Original Paper

Comparison of transcatheter arterial chemoembolization and microsphere embolization for treatment of unresectable hepatocellular carcinoma: a meta-analysis

Original Paper

Inhibition of Aurora kinases enhances chemosensitivity to temozolomide and causes radiosensitization in glioblastoma cells

Original Paper

Trends in incidence, tumour sites and tumour stages of oral and pharyngeal cancer in Northern Germany

Original Paper

Functional outcome after different oncological interventions in head and neck cancer patients

Original Paper

Possible predictors of histopathological response to neoadjuvant chemoradiotherapy for rectal cancer
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits